Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion

The inauguration was attended by the Governor of New Jersey, Phil Murphy, who was the guest of honour, along with Biocon’s Chairperson Kiran Mazumdar-Shaw, and a distinguished gathering of dignitaries, customers, partners, and industry leaders. Biocon had acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and subsequently invested over USD 30 million to upgrade it into a state-of-the-art plant with an annual production capacity of two billion tablets. A few products have already been commercialised from the site, with several more in the pipeline. The company said the Cranbury facility represents a strategic advancement in its U.S. operations by enabling faster access to therapies, improved supply reliability, and stronger connections with partners and healthcare providers, ultimately benefitting patients across the United States. Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, “Biocon’s first U.S. FDA approved formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are.” She added that Governor Phil Murphy’s presence underscored Biocon’s role in fostering innovation, creating jobs, and strengthening the U.S. healthcare ecosystem. Siddharth Mittal, CEO and Managing Director of Biocon, commented that the strategic investment brings the company closer to patients and healthcare providers in this key market, allowing Biocon to deliver high-quality, vertically integrated medicines more efficiently across the U.S. and beyond. Governor Murphy welcomed the investment, calling the Cranbury site “a significant moment in Biocon’s global expansion” and one that reinforces New Jersey’s reputation as the “medicine chest to the world.”